Psoriazisli Hastalarda Serum Asimetrik Dimetilarjinin (ADMA) ve Yüksek Sensitif C-Reaktif Protein (hsCRP) Seviyeleri

Abstract

Aim: Asymmetric dimethylarginine (ADMA) is a major inhibitor of nitric oxide synthesis inhumans. Recent reports have demonstrated that elevated high sensitive C-reactive protein(hsCRP), an inflammatory marker, and plasma ADMA levels are associated with endothelialdysfunction and increased atherogenesis. We aimed to determine the presence of endothelialdysfunction in psoriatic patients and if psoriazis is an independent risk factor for cardiovasculardiseases by measuring the serum levels of ADMA and hsCRP in patients with psoriazis.Material and Methods: Thirty five psoriatic patients not having traditional cardiovascular riskfactors and 26 healthy controls were included into the study. Serum levels of ADMA, hsCRP,HDL, LDL, triglyceride, and total cholesterol, and BMI analyses were assessed and comparedbetween patient and control subjects. The association of psoriazis area and severity index (PASI)scores with ADMA and hsCRP levels were evaluated. Results: There was no statistically significant difference for the demographic characteristics,and all laboratory parameters levels between psoriazis and control groups. ADMA values were0.63±0.30 μmol/L (mean±sd) and 0.68±0.45 μmol/L (mean±sd) in patients and control group,respectively. hsCRP levels were 1.40±1.51 mg/L (mean±sd) in control group, while 1.91±2.13mg/L (mean±sd) in patients group. There was no statistically significant difference betweenpatients and control groups, in terms of ADMA and hsCRP values (p>0.05). Statisticallysignificance and moderate correlation was found between PASI scores and serum hsCRP levels(r=0,73; p<0,01).Conclusion: This study concludes that there isn’t an increasedvascular endothelial dysfunction which could be shown by ADMAand hsCRP biochemical markers in mild and moderate psoriazis.Also, it suggests that mild and moderate psoriazis is not anindependent risk factor for cardiovascular diseases. However, itis concluded that the levels of hsCRP could be used as an objectivemarker alternative to PASI to determine the response to thetreatment and the severity of the disease